{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:47:55Z","timestamp":1782928075117,"version":"3.54.5"},"reference-count":28,"publisher":"Tech Science Press","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJU"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/cju.2025.064710","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:14:26Z","timestamp":1741918466000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies"],"prefix":"10.32604","volume":"32","author":[{"given":"Badrinath R.","family":"Konety","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"ref2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ucl.2019.09.011","article-title":"Intravesical gene therapy","volume":"47","author":"Narayan","year":"2020","journal-title":"Urol Clin North Am"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"ref6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 4.2024 Plymouth Meeting, PA: National Comprehensive Cancer Network; 2024. [updated 05\/09\/2024]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","article-title":"Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series","volume":"184","author":"Stimson","year":"2010","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"ref12","unstructured":"KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use [package insert]. Rahway, NJ: Merck & Co., Inc; 2024."},{"key":"ref13","unstructured":"ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) suspension, for intravesical use. Kastrup, Denmark: Ferring Pharmaceuticals; 2022."},{"key":"ref14","unstructured":"VALSTAR\u00ae (valrubicin) solution, for intravesical use [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; 2019."},{"key":"ref15","unstructured":"ANKTIVA\u00ae (nogapendekin alfa inbakicept-pmln) solution, for intravesical use [package insert]. Culver City, CA: ImmunityBio Inc; 2024."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1359725","DOI":"10.3389\/fonc.2024.1359725","article-title":"Mechanism of action of nadofaragene firadenovec-vncg","volume":"14","author":"Narayan","year":"2024","journal-title":"Front Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"ref25","first-page":"157","article-title":"Managing the adverse events of intravesical Bacillus Calmette-Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e230849","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref27","unstructured":"Sharma A. Summary basis for regulatory action. Silver Spring, MD: US Food and Drug Administration; 2022. [updated 12\/16\/2022]. Available from: https:\/\/www.fda.gov\/media\/164532\/download."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"TPS705","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS705","article-title":"ABLE-41: nadofaragene firadenovec-vncg early use and outcomes in a real-world setting in the United States","volume":"42","author":"Daneshmand","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Canadian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/cju\/2025\/TSP_CJU_32-1\/TSP_CJU_64710\/TSP_CJU_64710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:33:39Z","timestamp":1763102019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/CJU\/v32n1\/60062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/cju.2025.064710","relation":{},"ISSN":["1488-5581"],"issn-type":[{"value":"1488-5581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}